Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JRoon, the question is, why would the entire past board and KM bail? They had Stock and Options that had not vested that they walked away from. Those decisions did not make dollars and sense. IMO
Denisk, send the info to the new management team and include AD. Maybe they will do something with the information.
RMB, I just received mine from Wells Fargo, Merrill Lynch and Edward Jones. Fidelity has not been received. Heading to golf course so won't have time to review until after lunch.
RMB, God may do something as we could be in the last days, but according to scripture, God will not destroy the earth with floods again.
jhc, part of the issue here is that you are talking about Revenue as Net Operating Profit or Net Income. Revenue by definition is Sales. Profit % or Profit $ are by definition the Net Profit from the operation of the business. That is the last figure at the bottom of the Income Statement. Revenue or Sales is the first line of the Income Statement / P & L.
jhc, jroon is correct. Inventory is carried on the books (Balance Sheet) as an asset. (Unless, it was expensed and paid for at time of purchase which for Amarin was not the case) Once sold it is converted to COGS against the sale (Revenue) and the result should be the Gross Margin to pay expenses and hopefully yeild a positive Net Operating Income.
If the inventory was written down to a lower cost basis then the results would be higher GM or reducing sell price to sell more against Generics.
I understand your statement that you don't have to purchase the product now (outflow of cash) but it doesn't benefit the bottom line Net Operating Income on the P & L.
RMB, I recall the reasoning exactly as you do. Wrong comparator and therefore pricing high in their opinion. And of course the whole EU market being bad played a part in the decision. For now.)
marjac, do you have any thoughts regarding the change and us now having Judge Kirsch?
marjac, I know you did a spectacular presentation of facts and that should have been more than enough to win the day, however Dyk and Reyna were not listening to any of it as their mind had already been made.
Terrible injustice to the rule of law.
Thanks again for all your valiant efforts and input.
marjac, thanks. Correct me if I'm wrong in that the FC judges are supposed to be a random selection and of course we got them twice. If we would get them again, it just confirms the belief that the court system against Amarin is rigged.
marjac, good to hear from you again. From your opinion, do you believe the GSK v. Teva will hold up through a bench trial should that occur?
Whal, AMRN sp never got close to $15 in '21 or '22. That price dates back to 2020 prior to the Duaster of 3/31/20.
Whal, I do not know the exact numbers or names of the various Sarissa companies, however, they initially purchased ~24M shares at over $100M. I don't know if by having these shares in various company and individual names mandates a 13F disclosure of more than a 1% position change up or down. But one of the post from yesterday? stated that his cost basis was $2.39 but I don't know if that was for the total 24M shares or a portion strictly under Sarissa Capital.
Capt, persistence. Your marketing skills and presentation of facts are great and you should pursue some capacity with the new management team. JMO
CaptBeer, thanks for posting the HLS V data.
Thanks JRoon71. I do not recall from other's prior posts, but what is the Canadian expected potential? TIA
Pharmacydude, I certainly respect your contributions and your opinion. And to much of it a agree. I'm not certain about AD sabotaging the process from the beginning as I don't have facts to agree or deny the allegations. I agree that there were strengths on the old board, but the continued allocations of free shares did not equate to the success of the company and shareholder value and for that I did hold some disdain for their actions. It appears that the urination contest between PWO and AD fueled a growing resentment overall and thus the entire old board stepped down and then KM. That, in my opinion was not the original plan. However, here we are and it will take some time for this to play out.
I only hope and pray that it does in a positive way for shareholders, patients and my sanity.
Thx
seve333, I'm sure they are since they walked away from all the free shares they awarded themselves. They won't be laughing when it goes up. And it will. JMO
PD, I was hoping you could put some color around the slow script growth in Canada with the assistance from Pfizer. I would have thought revenue would be higher.
TIA
PD, I have to say that I used to enjoy reading your posts as they were insightful of the actual script market in Canada and additional information regarding V. However, when Denner saw this undervalued company, invested $100M and ask for some representation on the board and PWO tried to stop him, the direction changed. We as shareholders wanted some help as the old guard had not done much in executing a positive plan. So AD's plan went from gaining 1-2 seats to adding more seats (in addition to the existing board) and of course remove the useless PWO. Sarissa won by a resounding landslide (77%) and of course those votes from the retail on this board certainly don't make up that 77%. Much came from tutes and HF. The departure of the entire board and the KM was on them, not AD. Why would they all walk away from the millions of shares they had been awarded? At the end of the day, we can look at many reasons for the script numbers remaining low and many of those are history. What matters today is what we do going forward. I voted BLUE as I was so very frustrated with the past management and can only wait for better days ahead.
But, to end where I started my response, you seem to have become very cynical in your defense of the old management due to Sarrisa not saving this company in the last two months. Personally, I will give them some more time. JMO
mms, I agree with BBI, that Denner wants a better return on his investment than from $4.50 to the $7-$8. He invested $110M+ because Amarin was way undervalued. It is a slow slog, but like some investments, the devil you know might be better than the devil you don't.
Of course I like everyone just have my opinion.
Whal, thanks for the explanation.
As most here are aware, but this article is a reminder / importance of having more awareness of the disease and the V solution.
https://www.msn.com/en-us/health/medical/ray-liotta-died-of-silent-killer-that-affects-half-of-us-adults-over-45/ar-AA1aUVWl?ocid=msedgntp&cvid=e66e7716f6bd47bbac90e2115f8bc6cb&ei=55
Whal, I am not sure how you can make money on a business producing $100K per month and have 15 employees. What type business?
And I think you know how AMRN can get to double digits but of course some of these things actually have to occur. Mitigate, Brave, EU, China, ROW, etc.
Pharmacydude, I have to agree with Jas on your personality change since the Sarrisa first attempting to gain a 'couple' of board seats. Your defense of KM and BOD are in my opinion over the top. The company was not being run other than through the rearview mirror and that is dangerous. PWO was a big problem and KM stuck with him. Denner invested over $100MM and PWO wouldn't give him the time of day. I don't think Denner's intention from the start was to take over the company but PWO's arrogance got him and the remaining board stepped aside and KM followed. They / he could have stayed.
So, as I see it, there are still a lot of unanswered questions regarding the sp. Teva/GSK, Mitigate, Brave, FDC, EU approvals, China, etc. but they can't come soon enough. I grow weary of reading the frustration on this board. I agree with you in that it used to be a well informed group of investors with positive contributions, but time and the frustration with everything that has happened (or not happened that are too many to list) has turned many posters more cynical.
I pray for better days ahead.
Take care.
sts66, the periods you see on Capt's chart are for quarters. 3 month periods and should have 12 - 13 per quarter.
MMS, but I stand on the premise of nothing has changed regarding the opportunity for V. Amarin has changed but I believe for the better. It will just take a little time for the new board to make the necessary changes to drive this where Denner originally saw it going. JMO
MMS, I hear what you say but I don't think Denner put $100MM on the line to get a 33% return. Remember he bought at ~$4.50 and to take a $6 BO now in my opinion will never happen. Things are certainly not worse than when he took his position. Hey, I'm frustrated too but I'll give him a little time to get this turned around.
whal, I agree with Capt regarding paralysis by analysis. V has proven to be effective. Scripts have stalled due to lack of marketing which is due to generics infringing on V. There needs to be more education / marketing to the cards and a win on the GSK / Teva as well as our Hikma case to open that possibility in the US.
NP. Just looks like everything was divided by 9 for the averages.
Capt, I love your charts, but I noticed that the averages are lower than any of the eight weeks numbers. Am I misinterpreting the data?
Thanks for doing all that you do to promote V.
I don't know how many people are golf enthusiast, but if you watched the Masters tournament last week there is little doubt that you heard the incredible and hearty felt story of the amateur Sam Bennett. Sam is at Texas A & M on their golf team and won the NCAA tournament this year and was allowed to play in the Masters, Sam's dad was diagnosed at age 45 with AD/Dementia and passed away a year or so ago, but before his passing he scribbled a note to Sam which was simple but powerful. "Don't wait to do something". Sam had that tatooed on the inside of his list to remind him.
I do not know if Vascepa would have prolonged his Dad's life, but I believe we agree it would have.
I implore Alex Denner to that very thing. "Don't wait to do something". Let's get this wonderful drug to the patients that need it.
BBI, I don't follow your comment on the board giving themselves a big payout. Granted, they did approve their options and RSU's, but they vest over 3-4 years. And then if they 'resign', would they actually vest or would they not lose them?
They did spend millions in their attempt to keep Denner out of the boardroom.
Capt, I agree. The change was due to the old BOD's resigning. That is not a COC as per normal agreements. Then KM resigned. He was not fired. That should be no difference in any employee 'quitting' versus being let go. If let go other than for cause, an individual would be entitled to some severance, etc. When quitting, you would not receive anything. You give up any rights. Period. JMO
Robin, to my knowledge KM had not invested $1 of his own money as he was granted plenty free options and RSU's. Of course now he thinks he deserves more since his little empire left and he then did the same. ATM machine ran out of free money.
Ram, I believe some of his 'performance bonus' was tied to getting the EU countries onboarded and he got some of those with the exception of the biggest prize Germany. Oh, and let's not forget Puerto Rico.
You set low bars and you might crawl over them. He didn't come in to the position with it in good shape, however, you don't make $6M in annual salary, bonus and stock for the dismal performance of the company.
J, you may be right in that only PWO was fighting but based on actions since their loss and now his (forced resignation), I think KM was probably fighting Sarrisa as well.
At a minimum claw back $7MM he spent on fighting Sarrisa. He certainly doesn't deserve anything as the door swings and hits him in the A$$ on the way out.
RMB, Yes. That's the generic world, but as we agree in this situation it really stinks that they can steal the market and the label. I know theirs in for trigs, but that's before the infringement off the skinny label
thanks dogn. What's particularly frustrating to me is that Hikma has their warnings on the label 'In a double blinded placebo trial' that they didn't spend a dime or time in testing. I'm too simple minded and fair, but it seems they should not be able to reference anything since they didn't test it.